血透患者使用冲击量1.25（OH）2D3治疗钙磷代谢紊乱的临床观察  

CLINICAL OBSERVATION OF IMPACT-DOSAGE OF ROCALTROL ON DIALYSIS PATIENTS WITH PHOSPHORUS-CALCIUM DYSBOLISM

作　　者：王学敏[1] 

机构地区：[1]天津市第一中心医院,天津300192

出　　处：《世界元素医学》2005年第4期29-31,共3页

摘　　要：目的观察1．25（OH）2D3（罗钙全）口服冲击剂量对纠正血液透析患者血清钙、磷代谢紊乱的疗效及甲状旁腺功能的影响。方法选择36例血液透析患者为治疗口服，1．25（OH）2D3剂量2-4ug／次，每周2次；选择32例常规治疗组剂量0．25ug／次，每天一次；10例为正常健康人对照组。结果冲击量治疗组与常规治疗组，血清钙明显升高，血清磷降低，PTH在常规组轻度降低，而冲击量组显著降低，但无统计学意义，临床症状观察冲击组症状明显好转，治疗过程中无明显副作用。结论1.25（OH）2D3口服冲击量治疗血液透析患者血清钙磷代谢紊乱改善甲状旁腺功能亢进疗效较佳，不失临床治疗的好方法。The effect of orally taking impact-dosage of rocaltrol on rectifying serum calcium level, treatment of phosphorus dysbolism and parathyroid （PTH） function of dialysis patients was observed. Thirty six dialysis patients who take rocaltrol twice a week, 2-4ug each time, were selected as impact group; Thirty two dialysis patients who take rocaltrol daily, 0.25ug each time, were selected as regular group; 10 health targets were selected as control group. Result is that the level of serum calcium increased significantly and serum phosphorus decreased in impact and regular group; the level of PTH decreased slightly in regular group and sharply in impact group, but this is no statistics significance. In impact group, clinical symptom alleviated and the medicine produced few side effects. It is clear that the impact dosage of rocaltrol achieved a satisfied result in rectifying serum phosphorus-calcium dysbolism and improving PTH function.

关 键 词：血液透析 冲击治疗 钙磷代谢紊乱 1.25(OH)2D3 

分 类 号：R459.5[医药卫生—治疗学] R735[医药卫生—临床医学]